SIRT7 Loss Disrupts 2-Step X Dosage Compensation in Female Mice
Updated
Updated · Nature.com · Jun 10
SIRT7 Loss Disrupts 2-Step X Dosage Compensation in Female Mice
1 articles · Updated · Nature.com · Jun 10
Summary
Female Sirt7-knockout mice showed reduced fitness across their lifespan, with the study identifying SIRT7 as a key protector of female X-chromosome integrity.
Mouse experiments found SIRT7 preferentially localizes to sex chromosomes; without it, Xist is overexpressed, X-chromosome inactivation strengthens, and the active X becomes hyperacetylated, disorganized and prone to DNA damage.
That active-X disruption drives overexpression of X-linked genes, creating genome imbalance and amplifying X-chromosome upregulation—the second arm of dosage compensation against autosomes.
The findings link a sirtuin directly to sex-chromosome regulation and offer a mechanistic explanation for why SIRT7 biology can produce stronger effects in females than in males.
As SIRT7 guards female DNA, could targeting it become the next major breakthrough in women's health?
Could one protein's control over the X chromosome explain female risk for diseases like Alzheimer's?
If longevity proteins work differently in women, will anti-aging medicine need to become sex-specific?
Landmark 2026 Discovery: SIRT7 Safeguards Female X Chromosome Dosage Compensation and Genome Stability
Overview
A major breakthrough in June 2026 revealed that SIRT7 is a key regulator of X chromosome dosage compensation in mammals. This protein is especially enriched on the X chromosome in female cells, where it acts as a genetic safeguard. SIRT7 maintains the balance of gene activity between the two X chromosomes by preventing excessive silencing of the inactive X and curbing overactivation of the active X. This ensures proper dosage compensation, which is essential for healthy cell function. Without SIRT7, gene activity becomes imbalanced, leading to genome instability and health problems, especially in females.